Table 2.

Prevalence of demographic and clinical characteristics in men with prostate cancer living in outer regional/remote areas of Tasmania relative to their counterparts living in inner regional areas.

	Unadjusted PR (95% CI)	Adjusted* PR (95% CI)	Adjusted† PR (95% CI)
Age at diagnosis
< 60	n.a
60–64	0.69 (0.55–0.86)
65–69	1.26 (1.07–1.50)
≥ 70	1.14 (1.02–1.28)
SEIFA quintile
1 (Most disadvantaged)	n.a	n.a
2	3.12 (2.63–3.70)	3.13 (2.63–3.72)
3	2.53 (2.03–3.14)	2.56 (2.04–3.20)
4	0.55 (0.45–0.68)	0.56 (0.45–0.69)
5 (Most advantaged)	0.11 (0.07–0.16)	0.10 (0.07–0.15)
Method of diagnosis
TRUS	n.a	n.a
TURP	1.13 (0.85–1.50)	0.94 (0.74–1.19)
TP Biopsy	1.05 (0.97–1.13)	1.07 (0.99–1.15)
Other	0.97 (0.47–1.98)	0.81 (0.40–1.64)
Diagnostic PSA (ng/mL)
≤ 4	n.a	n.a	n.a
4.01–10	0.92 (0.83–1.01)	0.99 (0.90–1.08)	1.00 (0.90–1.11)
10.01–20	1.35 (1.13–1.62)	1.24 (1.02–1.49)	1.11 (0.93–1.32)
> 20.01	1.10 (0.84–1.45)	0.91 (0.73–1.14)	0.88 (0.75–1.02)
Gleason score
< 7	n.a	n.a	n.a
7 (3 + 4)	0.99 (0.84–1.17)	1.04 (0.87–1.23)	1.08 (0.90–1.3)
7 (4 + 3)	1.27 (1.01–1.59)	1.20 (0.94–1.53)	1.02 (0.78–1.3)
≥ 8	1.21 (1.02–1.43)	0.98 (0.82–1.16)	1.20 (0.99–1.46)
NCCN risk
Low	0.70 (0.58–0.84)	0.75 (0.62–0.89)	0.88 (0.73–1.08)
Intermediate	n.a	n.a	n.a
high	1.30 (1.11–1.52)	1.31 (1.13–1.52)	1.22 (1.01–1.47)
Very high/metastatic	0.99 (0.74–1.32)	0.99 (0.74–1.31)	0.87 (0.58–1.29)
Diagnostic facility
Public	n.a	n.a
Private	0.82 (0.76–0.88)	0.82 (0.76–0.87)
Treatment facility (active treatment)
Public	n.a	n.a
Private	0.83 (0.72–0.95)	0.84 (0.73–0.97)

PR = Prevalence Ratio; CI = Confidence Interval; n.a. = Not Applicable; SEIFA = Socio-Economic Index of Advantage and Disadvantage; TRUS = Transrectal Ultrasound; TURP = Transurethral Resection of the Prostate; TP Biopsy = Transperineal Biopsy; PSA = Prostate Specific Antigen; NCCN = National Comprehensive Cancer Network.

*Adjusted for age at diagnosis.

^†Adjusted for age at diagnosis, SEIFA index, method of diagnosis and type of diagnostic facility.